



Ocera Therapeutics, Inc.  
Investor Relations Department  
5001 S. Miami Boulevard,  
Suite 300  
Durham, NC 27703  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: OCRX

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 1.77                       |
| Trade Time:   | 4:00 PM ET<br>Nov 17, 2017 |
| Change:       | 0.02<br>(+1.143%)          |
| Day Range     | 1.73 - 1.77                |
| 52-Week Range | 0.52 - 2.95                |
| Volume        | 203,948                    |

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

[Ocera Therapeutics](#)  
(NASDAQ:OCRX) is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with serious diseases in areas of high unmet medical need.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Nov 2, 2017*  
[Mallinckrodt to Acquire Ocera Therapeutics and OCR-002, its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy](#)
- Oct 20, 2017*  
[Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting®](#)
- Aug 23, 2017*  
[Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting® 2017](#)
- Aug 1, 2017*  
[Ocera Therapeutics Reports Second Quarter 2017 Financial Results](#)
- Jun 1, 2017*  
[Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Mar 14, 2017*  
[Annual Report \(10-K\)](#)
- Apr 25, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 14, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 1, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*  
[Quarterly Report \(10-Q\)](#)